Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Community Connections: EvoLV's Role in Eastvale's Biotech Growth

Jul 16, 2026By Sreejith Kanhirangadan

SK

Introduction to Eastvale's Biotech Rise

In recent years, Eastvale has emerged as a burgeoning hub for biotech innovation, attracting startups and established companies alike. This transformation is largely due to the community's commitment to fostering an environment ripe for technological advancements and research breakthroughs.

At the heart of this evolution is EvoLV, a dynamic player in the biotech sector, known for its cutting-edge research and development initiatives. Their presence in Eastvale has not only spurred economic growth but also positioned the city as a key player in the global biotech landscape.

eastvale skyline

EvoLV's Contribution to Economic Growth

EvoLV has been instrumental in driving Eastvale's economic development. By creating numerous job opportunities, the company has significantly reduced unemployment rates in the region. This influx of new jobs has attracted skilled professionals, further boosting the local economy and supporting ancillary businesses.

Moreover, EvoLV's investment in research facilities and laboratories has led to increased business for local suppliers and service providers. This symbiotic relationship between EvoLV and the community underscores the importance of collaboration in achieving sustainable growth.

biotech lab

Partnering with Local Institutions

A key element of EvoLV's strategy involves partnering with local educational and research institutions. By collaborating with universities and colleges, EvoLV has been able to tap into a pool of fresh talent and innovative ideas. These partnerships have resulted in groundbreaking research projects and training programs that equip students with the skills needed in the biotech industry.

Through internships and mentorship opportunities, EvoLV ensures that students gain practical experience, preparing them for successful careers in biotechnology. This commitment to education and workforce development is a testament to EvoLV's dedication to community growth.

students in lab

Community Engagement and Support

EvoLV is deeply committed to engaging with the Eastvale community beyond economic contributions. The company regularly hosts workshops and seminars that are open to the public, providing valuable insights into the latest biotech trends and innovations. These events not only educate but also inspire community members to participate in the biotech field.

Additionally, EvoLV supports local non-profits and community initiatives, demonstrating a strong commitment to social responsibility. By investing in community welfare, EvoLV strengthens its ties with Eastvale residents and fosters a sense of shared purpose.

community event

Future Prospects for Eastvale's Biotech Industry

Looking ahead, the future of Eastvale's biotech industry appears promising. With EvoLV leading the charge, the city is poised to become a major player in the global biotech arena. The continued support from local government, institutions, and businesses will be crucial in maintaining this upward trajectory.

As new technologies and innovations emerge, Eastvale's biotech sector is expected to diversify further, opening up new avenues for research and development. This evolution will not only benefit the local economy but also contribute to advancements in healthcare and technology on a broader scale.

Conclusion

EvoLV's role in Eastvale's biotech growth is a testament to the power of community collaboration and innovation. By fostering economic development, partnering with local institutions, and engaging with the community, EvoLV has laid the groundwork for a thriving biotech industry.

As Eastvale continues to grow and evolve, its residents can look forward to a future brimming with opportunities and advancements, thanks in large part to the efforts and vision of EvoLV.